Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Poll|Articles|April 18, 2024
Are You Attending the 2024 APA Annual Meeting?
Author(s)Psychiatric Times Editors
Let us know if we'll see you there!
Advertisement
We'll be on the ground live at the 2024 American Psychiatric Association Annual Meeting in New York. Will we see you there?
Are you attending the 2024 APA Annual Meeting live in New York?
What's your favorite kind of conference coverage content?
If you cannot attend, you can keep up with all our latest coverage here at psychiatrictimes.com!
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
2
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
3
The New, Impending Adult ADHD Guidelines
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5